EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase) • CD4 (CD4 Molecule)

EGFR mutation • EGFR amplification • IDH wild-type

lomustine • carmustine • VBI-1901

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov)

P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

5 days ago

Trial completion

CD34 (CD34 molecule)

cyclophosphamide • etoposide IV • carmustine

16d

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (clinicaltrials.gov)

P2, N=50, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Jun 2031 | Trial primary completion date: Jun 2022 --> Jun 2030

16 days ago

Trial completion date • Trial primary completion date

cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Epidaza (chidamide) • carmustine

18d

Prognostic Stratification and Subtyping of Glioblastoma Using Transient Receptor Potential Channels. (PubMed, Hum Mutat)

High TRPRS was associated with diminished cytotoxic T-cell infiltration and predicted resistance to multiple therapeutics-including cisplatin, carmustine, gefitinib, buparlisib, and afatinib. Functional assays demonstrated that IFNGR2 knockdown suppressed glioma cell proliferation and attenuated NF-κB signaling, underscoring its role as a key driver within the TRP network. TRPRS provides a robust, biologically grounded tool for simultaneous prognostication and therapy guidance in GBM, highlighting TRP signaling as a therapeutic vulnerability.

18 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)

TP53 mutation

cisplatin • Gilotrif (afatinib) • gefitinib • buparlisib (AN2025) • carmustine

19d

CAR-T+ASCT: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (clinicaltrials.gov)

P2, N=20, Not yet recruiting, Zhejiang Cancer Hospital

19 days ago

New P2 trial

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

TP53 mutation

cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) (clinicaltrials.gov)

P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2026 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Mar 2031

1 month ago

Trial completion date • Trial primary completion date

cyclophosphamide • topotecan • carmustine

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma (clinicaltrials.gov)

P2, N=49, Recruiting, VIVUS LLC | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

1 month ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

carmustine

2ms

IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov)

P2, N=227, Completed, International Extranodal Lymphoma Study Group (IELSG) | N=126 --> 227

2 months ago

Enrollment change

Rituxan (rituximab) • cytarabine • carmustine • thiotepa • methotrexate IV

2ms

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)

P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027

2 months ago

Enrollment closed • Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • carmustine • melphalan

2ms

A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. (PubMed, Front Mol Biosci)

As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.

2 months ago

FDA event • Journal

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)

lomustine • carmustine • Voranigo (vorasidenib)

2ms

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P3, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

2 months ago

Trial completion date

BCL2 (B-cell CLL/lymphoma 2)

Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)

3ms

ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)

The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.

3 months ago

Journal

ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK positive • ALK fusion • ALK translocation

Rituxan (rituximab) • carmustine